The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
While Cogent joins the FGFR party.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Just when investors thought things couldn't get any worse, they do.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
